532305 Stock Overview
Develops, manufactures, and sells active pharmaceutical ingredients (APIs), intermediates, and formulations in India and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 5/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Ind-Swift Laboratories Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹104.70 |
| 52 Week High | ₹186.00 |
| 52 Week Low | ₹87.00 |
| Beta | 0.37 |
| 1 Month Change | -4.38% |
| 3 Month Change | -6.93% |
| 1 Year Change | -10.13% |
| 3 Year Change | 38.95% |
| 5 Year Change | 399.76% |
| Change since IPO | -38.56% |
Recent News & Updates
Recent updates
Shareholder Returns
| 532305 | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | -3.6% | 3.4% | 1.6% |
| 1Y | -10.1% | 19.3% | 5.5% |
Return vs Industry: 532305 underperformed the Indian Pharmaceuticals industry which returned 18.4% over the past year.
Return vs Market: 532305 underperformed the Indian Market which returned 5.8% over the past year.
Price Volatility
| 532305 volatility | |
|---|---|
| 532305 Average Weekly Movement | 6.1% |
| Pharmaceuticals Industry Average Movement | 6.1% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in IN Market | 9.1% |
| 10% least volatile stocks in IN Market | 4.3% |
Stable Share Price: 532305 has not had significant price volatility in the past 3 months compared to the Indian market.
Volatility Over Time: 532305's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1995 | 47 | Navrattan Munjal | www.indswiftlabs.com |
Ind-Swift Laboratories Limited, together with its subsidiaries, develops, manufactures, and sells active pharmaceutical ingredients (APIs), intermediates, and formulations in India and internationally. The company offers APIs in various therapeutic areas, including macrolide antibiotic, cardiovascular, antihistaminic, antidiabetic, antipsychotic, bone resorption inhibitor, Parkinson’s disease, hyperparathyrodism, analgesic, aromatase inhibitor, nootropic, antidiarrhoeal/antiprotozoal, alcohol abstinence, antineoplastic, ADHD symptoms, anticancer, hypercholesterolemia, antimigraine, and thrombocytopenia. It also provides reference standards and impurities for acamprosate calcium, anastrozole, aripiprazole, atorvastatin calcium, azithromycin dihydrate, bexarotene, cinacalcet hydrochloride, clopidogrel bisulphate, clopidogrel hydrochloride, dapoxetine hydrochloride, donepezil hydrochloride, ezetimibe, fexofenadine hydrochloride, imatinib mesylate, ivabradine hydrochloride, ivabradine oxalate, letrozole, mecloxamine citrate, naratriptan hydrochloride, nateglinide, nitazoxanide, nitrosamine, pazopanib hydrochloride, quetiapine hemifumarate, raltegravir potassium, ropinirole hydrochloride, rosuvastatin calcium, saxagliptin monohydrate, silodosin, and temozolomide, as well as contract research and manufacturing services.
Ind-Swift Laboratories Limited Fundamentals Summary
| 532305 fundamental statistics | |
|---|---|
| Market cap | ₹6.21b |
| Earnings (TTM) | ₹3.73b |
| Revenue (TTM) | ₹7.42b |
1.7x
P/E Ratio0.8x
P/S RatioIs 532305 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 532305 income statement (TTM) | |
|---|---|
| Revenue | ₹7.42b |
| Cost of Revenue | ₹3.90b |
| Gross Profit | ₹3.52b |
| Other Expenses | -₹214.46m |
| Earnings | ₹3.73b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Feb 14, 2025
| Earnings per share (EPS) | 63.20 |
| Gross Margin | 47.41% |
| Net Profit Margin | 50.30% |
| Debt/Equity Ratio | 1.6% |
How did 532305 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/06 10:04 |
| End of Day Share Price | 2025/02/06 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Ind-Swift Laboratories Limited is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Hitesh Kuvelkar | First Global Stockbroking (P) Ltd. |